Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

被引:502
作者
Siegel, Dustin [1 ]
Hui, Hon C. [1 ]
Doerffler, Edward [1 ]
Clarke, Michael O. [1 ]
Chun, Kwon [1 ]
Zhang, Lijun [1 ]
Neville, Sean [1 ]
Carra, Ernest [1 ]
Lew, Willard [1 ]
Ross, Bruce [1 ]
Wang, Queenie [1 ]
Wolfe, Lydia [1 ]
Jordan, Robert [1 ]
Soloveva, Veronica [2 ]
Knox, John [1 ]
Perry, Jason [1 ]
Perron, Michel [1 ]
Stray, Kirsten M. [1 ]
Barauskas, Ona [1 ]
Feng, Joy Y. [1 ]
Xu, Yili [1 ]
Lee, Gary [1 ]
Rheingold, Arnold L. [3 ]
Ray, Adrian S. [1 ]
Bannister, Roy [1 ]
Strickley, Robert [1 ]
Swaminathan, Swami [1 ]
Lee, William A. [1 ]
Bavari, Sina [1 ,2 ]
Cihlar, Tomas [1 ]
Lo, Michael K. [4 ]
Warren, Travis K. [2 ]
Mackman, Richard L. [1 ]
机构
[1] Inc, Gilead Sci, Foster City, CA 94404 USA
[2] United States Army Med Res Inst Infect Dis USAMR, Frederick, MD 21702 USA
[3] Univ Calif San Diego, San Diego, CA 92093 USA
[4] Centers Dis Control & Prevent, Atlanta, GA 30333 USA
关键词
ANTIVIRAL ACTIVITY; MITOCHONDRIAL RNA; T-705; FAVIPIRAVIR; 4-AZA-7,9-DIDEAZAADENOSINE; TRANSMISSION; REPLICATION; POLYMERASE; INHIBITOR; INFECTION; EFFICACY;
D O I
10.1021/acs.jmedchem.6b01594
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The recent Ebola virus (EBOV) outbreak in West Africa was the largest recorded in history with over 28,000 cases, resulting in >11,000 deaths including >500 healthcare workers. A focused screening and lead optimization effort identified 4b (GS-5734) with anti-EBOV EC50 = 86 nM in macrophages as the clinical candidate. Structure activity relationships established that the l'-CN group and C-linked nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases. A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclinical efficacy in a non-human-primate EBOV challenge model. Once-daily 10 mg/kg iv treatment on days 3-14 postinfection had a significant effect on viremia and mortality, resulting in 100% survival of infected treated animals [Nature 2016, 531, 381-385]. A phase 2 study (PREVAIL IV) is currently enrolling and will evaluate the effect of 4b on viral shedding from sanctuary sites in EBOV survivors.
引用
收藏
页码:1648 / 1661
页数:14
相关论文
共 44 条
[41]   Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 [J].
Warren, Travis K. ;
Wells, Jay ;
Panchal, Rekha G. ;
Stuthman, Kelly S. ;
Garza, Nicole L. ;
Van Tongeren, Sean A. ;
Dong, Lian ;
Retterer, Cary J. ;
Eaton, Brett P. ;
Pegoraro, Gianluca ;
Honnold, Shelley ;
Bantia, Shanta ;
Kotian, Pravin ;
Chen, Xilin ;
Taubenheim, Brian R. ;
Welch, Lisa S. ;
Minning, Dena M. ;
Babu, Yarlagadda S. ;
Sheridan, William P. ;
Bavari, Sina .
NATURE, 2014, 508 (7496) :402-+
[42]  
World Health Organization, 2016, EB DAT STAT 11 MAY 2
[43]   Synthesis and biological evaluation of 1'-C-cyano-pyrimidine nucleosides [J].
Yoshimura, Y ;
Kano, F ;
Miyazaki, S ;
Ashida, N ;
Sakata, S ;
Haraguchi, K ;
Itoh, Y ;
Tanaka, H ;
Miyasaka, T .
NUCLEOSIDES & NUCLEOTIDES, 1996, 15 (1-3) :305-324
[44]   Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime [J].
Zhao, L. ;
Kroenke, C. D. ;
Song, J. ;
Piwnica-Worms, D. ;
Ackerman, J. J. H. ;
Neil, J. J. .
NMR IN BIOMEDICINE, 2008, 21 (02) :159-164